Massachusetts, US-based sciences and healthcare services provider PerkinElmer, Inc. (NYSE: PKI) has agreed to acquire California-based life science antibodies and reagents provider BioLegend, for approximately USD 5.25bn, in a combination of cash and stock, the company said.
BioLegend provides its academic and biopharmaceutical customers with antibodies and reagents in high-growth areas such as cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation and bioprocessing.
The transaction will be the largest in PerkinElmer's history and is expected to close by the end of the 2021 calendar year, subject to regulatory approvals and other customary closing conditions.
Upon joining PerkinElmer, BioLegend will expand PerkinElmer's existing life science franchise into new segments, and its campus in San Diego, California will become PerkinElmer's global Centre of Excellence for research reagent content development for the combined company.
Goldman Sachs and Co. LLC, Inc., is serving as exclusive financial advisor to PerkinElmer, with WilmerHale serving as legal counsel and McDermott Will and Emery serving as antitrust counsel. J.P. Morgan Securities LLC is serving as exclusive financial advisor to BioLegend with Pillsbury Winthrop Shaw Pittman LLP serving as legal counsel.
Industrial Blue Laser Technology Specialist Nuburu Closes Merger with SPAC
Crisp Acquires Electronic Data Interchange Platform Integral Group
HdL Companies Acquires DataMax Revenue Enhancement
Plusgrade Acquires UpStay to Expand Portfolio in Hospital Industry
Lexitas Acquires Kusar Court Reporters to Expand Growth in Western Market
Addtronics Acquires Missouri Tooling & Automation to Expand Robotic Automation Solutions
CropX Acquires Tule to Expand in Drip-Irrigated Specialty Crops Market in California
Highlander Partners Acquires Black Sage Technologies to Solidify Position in C-UAS Category
Precisely Acquires Transerve to Strengthen Data Enrichment and Analysis Capabilities